The company's lead product ZTlido® (lidocaine topical system) 1.8%, is a marketed prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN). The company develops three product candidates, including SP-102 (dexamethasone sodium phosphate viscous gel - SEMDEXA), SP-103 (lidocaine topical system) 5.4%, and SP-104 (low-dose naltrexone hydrochloride delayed-release capsules), positioning Scilex as a comprehensive non-opioid pain management player with expanding clinical pipeline.
Cyborg Score Rationale
The company is expected to post a final loss in 2025, before turning a profit of US$137m in 2026. However, the company currently has negative equity on its balance sheet, which can sometimes arise from accounting methods used to deal with accumulated losses from prior years. Recent developments suggest expansion beyond core pain management with healthcare investments.
Top Insights
Expected to achieve profitability in 2026 with analyst projections of US$137m profit, marking potential breakeven achievement
Recent strategic expansion into preventive diagnosis and prognosis markets through $20 million investment in Quantum Scan Holdings announced January 30, 2026
SP-102 (SEMDEXA) has completed Phase 3 study for lumbosacral radicular pain; SP-103 completed Phase 2 trial; SP-104 completed Phase 1 trials, representing advancing clinical stage candidates
Market capitalization of $48.33 million as of February 20, 2026, indicating small-cap positioning with significant upside/downside potential
Named Competitors
ZTlido/Lidoderm alternatives — Established topical anesthetic pain management
Epidural corticosteroid injections — Traditional treatment for radicular pain
Fibromyalgia treatments — Approved medications for chronic pain conditions
Recent Developments
(January 2026) Strategic $20 million investment in Quantum Scan Holdings targeting preventive diagnosis and medical technology markets
(January 2026) Appointment of Stephen Ma as Chief Operating Officer
(November 2025) Exercise of warrants generating $20.3 million gross proceeds and completion of Datavault AI investment tranches
Open the full interactive Scilex Holding Company report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.